Studies have shown that Herceptin significantly improves survival rates in patients with HER2-positive breast cancer. In early-stage breast cancer, it has been shown to reduce the risk of recurrence by approximately 50%. In metastatic breast cancer, it can prolong survival and improve the quality of life.